Potential $330M Deal With Forest
Microbia's IBS Drug: Taking The Place Of Risky Zelnorm?
By Randall Osborne
Monday, September 24, 2007
Coming up with drugs that belong on the radar - and prescription pads - of primary-care doctors is "a challenge that biotech is treading carefully on," as Peter Hecht, CEO of Microbia Inc., told BioWorld Financial Watch last week, but Hecht's firm made a major footfall into the zone with its potential $330 million deal with Forest Laboratories Inc. (BioWorld Financial Watch)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.